Comparison of change in body weight between contraception containing 30-μg ethinylestradiol/2-mg chlormadinone acetate or 30-μg ethinylestradiol/3-mg drospirenone: a randomised controlled trial

References

• Zahradnik HP. Belara – a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur J Contracept Reprod Health Care. 2005;10:12–18.
   PubMed Web of Science ®Google Scholar
• Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;1:CD003987.
   PubMedGoogle Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003;46:S7–S16.
   PubMed Web of Science ®Google Scholar
• Borges LE, Andrade RP, Aldrighi JM, et al. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception 2006;74:446–450.
   PubMed Web of Science ®Google Scholar
• Tan J, Ediriweera C. Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne. Int J Womens Health 2009;1:213–221.
   Google Scholar
• Guang-Sheng F, Mei-Lu B, Li-Nan C, et al. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin Drug Investig. 2010;30:387–396.
   PubMed Web of Science ®Google Scholar
• Uras R, Orru M, Etzi R, et al. Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass. Contraception 2009;79:117–121.
   PubMed Web of Science ®Google Scholar
• Pushparajah DS, Rohm P, Hoschen K, et al. Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice. Clin Drug Investig. 2011;31:121–134.
   PubMed Web of Science ®Google Scholar
• Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1986;34:253–260.
   PubMed Web of Science ®Google Scholar
• Noppakun N, Timpatanapong P, Sindhupak W, et al. Clinical practice guideline for acne (in Thai). 2011. [cited 2011 September 28]. Available from: www.dst.or.th/files_news/001-Guideline_Acne_2011.pdf.
   Google Scholar
• Oddens BJ. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception. 1999;59:277–286.
   PubMed Web of Science ®Google Scholar
• Lindh I, Blohm F, Andersson-Ellstrom A, et al. Contraceptive use and pregnancy outcome in three generations of Swedish female teenagers from the same urban population. Contraception. 2009;80:163–169.
   PubMed Web of Science ®Google Scholar
• Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception. 2003;67:305–312.
   PubMed Web of Science ®Google Scholar
• Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) – an open-label, prospective, noncontrolled, office-based phase III study. Contraception. 2008;77:337–343.
   PubMed Web of Science ®Google Scholar
• Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Investig. 2010;30:211–220.
   PubMed Web of Science ®Google Scholar
• Schramm GA, Schrah G. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women. Contraception. 2011;84:390–401.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Lazzarini V, Ricci C, et al. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception. 2007;76:190–194.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Sandri M, Gerlinger C, et al. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight. Eur J Contracept Reprod Health Care. 2007;12:220–228.
   PubMed Web of Science ®Google Scholar
• Oelkers W, Helmerhorst FM, Wuttke W, et al. Effect of an oral contraceptive containing drospirenone on the renin–angiotensin–aldosterone system in healthy female volunteers. Gynecol Endocrinol. 2000;14:204–213.
   PubMed Web of Science ®Google Scholar
• Suthipongse W, Taneepanichskul S. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 µg ethinylestradiol and 150 microg levonorgestrel/30 µg ethinylestradiol in Thai women. Contraception. 2004;69:23–26.
   PubMed Web of Science ®Google Scholar
• Lello S, Primavera G, Colonna L, et al. Effects of two estroprogestins containing ethynilestradiol 30 µg and drospirenone 3 mg and ethynilestradiol 30 µg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol. 2008;24:718–723.
   PubMed Web of Science ®Google Scholar
• Sabatini R, Orsini G, Cagiano R, et al. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception. 2007;76:342–347.
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med. 2018;3:5.
   PubMedGoogle Scholar